JP Morgan analyst Alexander Hacking maintains MSCI (NYSE:MSCI) with a Overweight and raises the price target from $580 to $585.
Catalyst Pharmaceuticals Stock Reaches Resistance Level, Looks Ready To Break Out
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) shares are trading higher Wednesday although there looks to be no company-evident news to explain the jump in price. The stock is trading on above-average volume and trending on social media sites.